在轻度认知障碍的中国老年人中进行非药物增强 (MINE) 计划的多领域干预:多中心随机对照试验协议
Xiaochu Wu1, Tianyao Zhang2, Yanhao Tu3
1National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, China.
BMC neurology
|September 27, 2023
概括
本研究研究了一项针对中华老年轻度认知障碍 (MCI) 的多领域干预措施. 目标是通过定制的,以社区为基础的策略来保护大脑健康,建立一个有价值的研究数据库.
科学领域:
- 老年学是指老年学的学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 痴呆症是一种进展性神经退行性疾病,早期干预对大脑健康至关重要.
- 与西方人口相比,中国老年人表现出不同的健康意识和生活方式行为.
- 多领域非药物干预为轻度认知障碍 (MCI) 提供了协同效益,与其多因素性质保持一致.
研究的目的:
- 评估中国人口中MCI患者多领域干预策略的有效性.
- 创建一个全面的生物库和图像数据库,用于调查认知障碍的病原性.
- 根据文化特点,调整和验证基于社区的干预措施.
主要方法:
- 一个全国性的多中心,基于社区的随机受控试验 (RCT),涉及1080名50岁以上的参与者,在中国10个城市 (2020-2024年).
- 参与者被分配到社区内的非接触控制,健康教育或多领域干预小组.
- 多领域的干预整合了运动,营养,睡眠卫生,健康教育和正念冥想.
主要成果:
- 数据分析将使用统计软件 (SPSS 21.0,Python 3.0) 进行.
- 研究结果将通过图表和表格呈现.
- 研究方案强调严格的科学方法和质量控制.
结论:
- 高质量的社区干预研究需要强大的实验协议和科学严谨性.
- 在整个研究过程中,有效的质量控制和合规监测是必不可少的.
- 该研究涉及利益相关者的合规性,质量保证,风险减轻以及未来的研究方向.
相关概念视频
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
147
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
147
01:30Cognitive Development During Adulthood
142
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
142
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212